AC
CYTK icon

Armistice Capital’s Cytokinetics CYTK Stock Holding History

Armistice Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Buy
1,201,342
+436,804
+57% +$31.4M 1.25% 7
2026
Q1 		$50.4M Sell
764,538
-228,228
-23% -$14.5M 0.9% 17
2025
Q4 		$63.1M Sell
992,766
-204,102
-17% -$12.7M 0.75% 20
2025
Q3 		$65.8M Sell
1,196,868
-115,481
-9% -$4.76M 0.98% 13
2025
Q2 		$43.4M Buy
1,312,349
+288,959
+28% +$10.1M 0.75% 18
2025
Q1 		$41.1M Sell
1,023,390
-288,610
-22% -$13.3M 0.62% 35
2024
Q4 		$61.7M Sell
1,312,000
-584,575
-31% -$30.4M 0.84% 23
2024
Q3 		$100M Sell
1,896,575
-169,416
-8% -$9.44M 1.6% 9
2024
Q2 		$112M Buy
2,065,991
+540,303
+35% +$32.6M 1.41% 6
2024
Q1 		$107M Buy
+1,525,688
New +$118M 1.42% 7

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital's CYTK Position: Q2 2026 in Review

Armistice Capital increased its Cytokinetics (CYTK) stake by 57% in Q2 2026, buying an estimated $31.4M and bringing the position to 1,201,342 shares worth $102M. The position accounts for 1.25% of the portfolio, ranked #7.

Armistice Capital first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $112M in Q2 2024. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Armistice Capital held 1,201,342 shares of Cytokinetics worth $102M as of Q2 2026.
  • Armistice Capital bought 436,804 Cytokinetics shares in Q2 2026, an estimated $31.4M.
  • Cytokinetics made up 1.25% of Armistice Capital's portfolio in Q2 2026, its #7 holding.
  • Armistice Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
  • Armistice Capital's Cytokinetics position peaked at $112M in Q2 2024.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.